$145 M

REPH Mkt cap, 15-Oct-2018

$41.3 M

Recro Pharma Revenue Q2, 2018
Recro Pharma Gross profit (Q2, 2018)18.7 M
Recro Pharma Gross profit margin (Q2, 2018), %45.3%
Recro Pharma Net income (Q2, 2018)-25.2 M
Recro Pharma EBIT (Q2, 2018)-26.2 M
Recro Pharma Cash, 30-Jun-201848.9 M
Recro Pharma EV150.4 M

Recro Pharma Revenue Breakdown

Embed Graph

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Recro Pharma Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

52.0m69.3m71.8m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m

Gross profit

23.9m32.2m33.6m

Gross profit Margin, %

46%46%47%

R&D expense

7.9m12.3m33.3m33.1m

General and administrative expense

4.0m13.0m12.7m25.4m

Operating expense total

11.9m25.3m46.0m112.1m

Depreciation and amortization

2.6m

EBIT

(11.9m)(7.0m)(25.8m)(40.3m)

EBIT margin, %

(13%)(37%)(56%)

Interest expense

4.3m5.6m5.6m12.0m

Interest income

10.5k12.0k49.0k385.0k

Pre tax profit

(16.1m)(12.5m)(31.3m)(52.0m)

Income tax expense

15.6m1.1m1.9m

Net Income

(16.1m)3.0m(30.2m)(50.1m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m19.5m41.3m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m10.5m22.6m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m9.1m18.7m

Gross profit Margin, %

50%39%42%45%66%44%38%46%45%

R&D expense

227.0k1.8m3.6m1.8m2.8m2.7m7.8m8.3m7.0m7.8m7.1m8.4m18.6m

General and administrative expense

646.6k958.6k1.1m2.4m2.6m3.5m2.7m2.8m3.8m4.0m6.3m9.5m22.5m

Operating expense total

873.6k2.8m4.7m4.1m18.3m16.7m22.8m24.1m20.9m26.0m26.4m32.4m67.5m

Depreciation and amortization

646.0k1.3m

EBIT

373.0k(164.0k)(5.0m)(6.8m)(3.9m)(7.3m)(9.4m)(12.8m)(26.2m)

EBIT margin, %

2%(1%)(28%)(39%)(23%)(39%)(56%)(66%)(63%)

Interest expense

4.3m4.3m1.7m2.0m1.5m1.3m1.5m1.2m1.2m2.1m4.3m

Interest income

215.02.3k4.6k3.7k4.0k2.0k9.0k8.0k10.0k105.0k117.0k142.0k255.0k

Pre tax profit

(6.5m)(8.1m)(5.4m)(8.4m)(10.5m)(14.8m)(30.2m)

Income tax expense

(11.0k)195.0k(18.0k)293.0k1.7m2.4m5.1m

Net Income

(5.1m)(2.8m)(4.7m)(4.1m)(1.3m)(2.2m)(6.5m)(14.4m)(5.4m)(8.1m)(8.9m)(12.5m)(25.2m)

Recro Pharma Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

19.7m19.8m64.5m61.0m

Accounts Receivable

89.6k8.6m10.4m9.7m

Inventories

9.0m1.1m9.8m

Current Assets

20.4m38.7m84.8m87.3m

PP&E

37.9m37.3m39.1m

Goodwill

6.4m6.4m6.4m

Total Assets

20.4m138.7m183.0m186.2m

Accounts Payable

869.9k1.6m4.1m8.0m

Short-term debt

4.5m2.2m

Current Liabilities

1.4m9.5m16.3m49.9m

Long-term debt

11.9m25.2m22.2m53.6m

Total Debt

11.9m29.8m24.4m53.6m

Total Liabilities

111.4m157.4m

Common Stock

77.1k92.0k190.0k

Additional Paid-in Capital

52.9m71.3m132.7m140.0m

Retained Earnings

(34.1m)(31.1m)(61.3m)(111.3m)

Total Equity

18.9m40.4m71.6m28.8m

Debt to Equity Ratio

0.6 x0.7 x0.3 x

Debt to Assets Ratio

0.6 x0.2 x0.1 x

Financial Leverage

1.1 x3.4 x2.6 x6.5 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

29.9m27.8m23.9m16.6m15.7m28.3m14.9m14.8m24.8m19.5m8.7m46.3m48.9m

Accounts Receivable

35.8k86.8k80.2k15.0m9.6m12.2m11.5m12.4m12.3m10.1m9.8m11.7m

Inventories

9.6m8.6m7.6m6.7m9.8m7.8m6.9m10.0m8.1m

Current Assets

30.2m28.1m24.1m17.3m42.4m48.4m36.2m35.2m49.0m77.3m69.8m79.3m79.0m

PP&E

39.4m38.7m37.0m36.6m36.5m37.3m37.6m38.5m38.7m

Goodwill

6.7m6.7m6.4m6.4m6.4m6.4m6.4m6.4m6.4m

Total Assets

30.2m28.1m24.1m17.9m129.8m134.5m135.1m133.7m146.0m176.1m169.8m178.5m180.5m

Accounts Payable

32.4k400.2k682.2k552.7k767.0k781.0k2.0m1.8m1.9m3.0m3.4m4.3m6.4m

Short-term debt

9.1m13.7m4.9m5.4m1.5m

Current Liabilities

824.8k1.3m1.9m2.6m15.8m19.1m12.5m12.4m11.3m12.9m12.0m44.7m49.8m

Long-term debt

36.5m24.4m22.6m22.2m22.7m54.0m54.3m

Total Debt

45.6m38.0m27.4m27.6m24.2m54.0m54.3m

Total Liabilities

824.8k1.3m1.9m2.6m115.1m106.1m100.0m102.4m105.4m111.7m112.8m153.9m156.0m

Additional Paid-in Capital

52.4m52.6m52.7m53.5m54.2m70.0m72.6m76.7m91.4m133.6m135.1m145.4m158.0m

Retained Earnings

(25.9m)(30.6m)(38.2m)(39.5m)(41.7m)(37.6m)(45.5m)(50.9m)(69.4m)(78.2m)(121.0m)(133.7m)

Total Equity

29.4m26.8m22.2m15.3m14.7m28.4m35.0m31.3m40.6m64.4m57.0m24.6m24.5m

Financial Leverage

1 x1 x1.1 x1.2 x8.8 x4.7 x3.9 x4.3 x3.6 x2.7 x3 x7.3 x7.4 x

Recro Pharma Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1m)3.0m(30.2m)(50.1m)

Depreciation and Amortization

1.4k4.1m5.0m4.9m

Accounts Receivable

(51.2k)4.0m(1.8m)725.0k

Inventories

1.3m(325.0k)(1.1m)

Accounts Payable

1.1m2.2m8.5m

Cash From Operating Activities

(10.9m)8.5m(3.2m)

Purchases of PP&E

(2.4m)(3.8m)(6.2m)

Cash From Investing Activities

(55.1m)(3.8m)(10.3m)

Long-term Borrowings

(16.3m)(6.3m)(27.3m)

Cash From Financing Activities

30.5m46.7m51.7m23.9m

Interest Paid

4.9m4.5m5.3m

Income Taxes Paid

467.0k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(12.5m)(25.2m)

Depreciation and Amortization

1.3m2.7m1.3m2.5m3.8m1.2m2.4m1.2m2.5m

Accounts Receivable

2.6k38.4k(48.4k)9.4k(1.9m)309.0k(147.0k)(2.0m)

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(189.0k)1.7m

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)

Cash From Operating Activities

(815.9k)(2.7m)(6.6m)(3.0m)1.7m7.8m(2.4m)(5.4m)(4.2m)(7.1m)(11.0m)(14.8m)(24.2m)

Purchases of PP&E

(1.2m)(1.8m)(344.0k)(1.1m)(2.0m)(1.7m)(3.2m)(1.7m)(2.9m)

Cash From Investing Activities

(53.9m)(54.5m)(344.0k)(1.1m)(2.0m)(37.9m)(44.8m)(3.1m)505.0k

Long-term Borrowings

(2.6m)(2.6m)

Cash From Financing Activities

30.7m30.5m30.5m(125.0k)48.2m55.2m(2.1m)1.5m11.2m(2.1m)23.0k3.2m11.7m

Interest Paid

3.4m1.2m2.4m3.5m1.0m2.1m2.5m4.4m

Income Taxes Paid

467.0k

Recro Pharma Ratios

USDY, 2018

EV/EBIT

-5.7 x

EV/CFO

-6.2 x

Financial Leverage

7.4 x
Report incorrect company information

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Report incorrect company information